Impact of Implantation of an LAA Occluder on ANP and BNP Level and Quality of Life

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03085667

Enrollment

Registered

2017-03-21

Start date

2011-01-31

Completion date

2015-12-31

Last updated

2020-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Left atrial appendage occluder, Watchman device, Atrial fibrillation, atrial natriureitc peptide, brain natriuretic peptide

Brief summary

Closure of the LAA by several devices is a alternative therapy to oral anticoagulation in patients with Atrail fibrillation. Nothing is known about the acute influence of a device closure of the LAA on the secretion of ANB nad BNP hormones. Therefore aim of our study is to measure ANB and BNP levvels before and after Implantation of an LAA closure device.

Detailed description

ANB and BNP levels are measured before, directly after and late after 24 h in central or periphereal venous blood from patients undergoing interventional LAA closure.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients undergoing LAA closure

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline atrial natriuretic Peptide (ANP)	24 h post intervention	comparison of ANP level pre and post intervention

Countries

Germany

Outcome results